ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,862.06
      -0.95%
      US Tech 100
      20,449.60
      -0.78%
      Dow Jones
      42,305.18
      -0.77%
      Brent Oil
      79.665
      3.56%
      Bitcoin
      94,057.77
      1.82%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Compass Therapeutics Inc (CMPX) Quote

      Compass Therapeutics Inc

      Compass Therapeutics Inc (CMPX)

      NASDAQ
      1.86
      0.43
      (30.07%)
      Closed January 08 4:00PM
      Delayed by 15 minutes
      1.9499
      0.0899
      ( 4.83% )
      Pre Market: 9:28AM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      1.9499
      Bid
      1.93
      Ask
      1.94
      Volume
      476,372
      0.00 Day's Range 0.00
      0.765 52 Week Range 2.68
      Market Cap
      268.285M
      Previous Close
      1.86
      Open
      -
      Last Trade
      5
      @
      1.9399
      Last Trade Time
      09:28:35
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      869,425
      Shares Outstanding
      137,589,171
      Dividend Yield
      -
      PE Ratio
      -6.02
      Earnings Per Share (EPS)
      -0.31
      Revenue
      -
      Net Profit
      -42.49M

      About Compass Therapeutics Inc

      Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engi... Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.compasstherapeutics.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Compass Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CMPX. The last closing price for Compass Therapeutics was $1.86. Over the last year, Compass Therapeutics shares have traded in a share price range of $ 0.765 to $ 2.68.

      Compass Therapeutics currently has 137,589,171 shares outstanding. The market capitalization of Compass Therapeutics is $255.92 million. Compass Therapeutics has a price to earnings ratio (PE ratio) of -6.02.

      Ask ADVFN Intelligence (AI)

      CMPX Latest News

      More News

      Another Day, Another Biotech Stealing The Show

      A biotech company based out of Boston turned heads on Wednesday after the company announced the advancement of anew drug candidate as well as provided a key update on existing To read the full...

      January 08 2025
      AllPennyStocks.com

      Form 8-K - Current report

      January 08 2025
      Edgar (US Regulatory)

      Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

      Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.CTX-10726 (a novel PD-1 x...

      January 08 2025
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      December 10 2024
      Edgar (US Regulatory)

      Form 3 - Initial statement of beneficial ownership of securities

      December 10 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      December 10 2024
      Edgar (US Regulatory)

      Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

      BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

      December 10 2024
      GlobeNewswire Inc.

      Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

      BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

      December 02 2024
      GlobeNewswire Inc.

      Compass Therapeutics to Participate in Upcoming Investor Events

      BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

      November 13 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      November 12 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.509935.40972222221.442.681.42564614371.83990108CS
      40.399925.81.552.681.3317715261.78428687CS
      120.03992.08900523561.912.681.278694251.72251459CS
      261.0469115.9357696570.9032.680.87416366821.61382392CS
      520.02991.557291666671.922.680.7655213671.61018508CS
      156-1.2601-39.25545171343.215.650.7653711692.25704223CS
      260-2.1501-52.44146341464.15.650.7653410082.30303241CS

      CMPX - Frequently Asked Questions (FAQ)

      What is the current Compass Therapeutics share price?
      The current share price of Compass Therapeutics is $ 1.9499
      How many Compass Therapeutics shares are in issue?
      Compass Therapeutics has 137,589,171 shares in issue
      What is the market cap of Compass Therapeutics?
      The market capitalisation of Compass Therapeutics is USD 255.92M
      What is the 1 year trading range for Compass Therapeutics share price?
      Compass Therapeutics has traded in the range of $ 0.765 to $ 2.68 during the past year
      What is the PE ratio of Compass Therapeutics?
      The price to earnings ratio of Compass Therapeutics is -6.02
      What is the reporting currency for Compass Therapeutics?
      Compass Therapeutics reports financial results in USD
      What is the latest annual profit for Compass Therapeutics?
      The latest annual profit of Compass Therapeutics is USD -42.49M
      What is the registered address of Compass Therapeutics?
      The registered address for Compass Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the Compass Therapeutics website address?
      The website address for Compass Therapeutics is www.compasstherapeutics.com
      Which industry sector does Compass Therapeutics operate in?
      Compass Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      AALAmerican Airlines Group Inc
      $ 17.60
      (0.00%)
      		3.71M
      AAGRAfrican Agriculture Holdings Inc
      $ 0.1326
      (0.00%)
      		0
      AADRAdvisorShares Dorsey Wright ADR ETF
      $ 71.1445
      (0.00%)
      		0
      AADIAadi Bioscience Inc
      $ 3.60
      (0.00%)
      		2.73k
      AACGATA Creativity Global
      $ 0.9791
      (0.00%)
      		1.02k
      AALAmerican Airlines Group Inc
      $ 17.60
      (0.00%)
      		3.71M
      AAGRAfrican Agriculture Holdings Inc
      $ 0.1326
      (0.00%)
      		0
      AADRAdvisorShares Dorsey Wright ADR ETF
      $ 71.1445
      (0.00%)
      		0
      AADIAadi Bioscience Inc
      $ 3.60
      (0.00%)
      		2.73k
      AACGATA Creativity Global
      $ 0.9791
      (0.00%)
      		1.02k
      CDTConduit Pharmaceuticals Inc
      $ 0.082
      (0.00%)
      		154.93M
      GRYPGryphon Digital Mining Inc
      $ 0.3772
      (0.00%)
      		34.53M
      VMARVision Marine Technologies Inc
      $ 1.52
      (0.00%)
      		29.99M
      IINNInspira Technologies Oxy B H N Ltd
      $ 1.00
      (0.00%)
      		23.16M
      RGTIRigetti Computing Inc
      $ 10.04
      (0.00%)
      		23.16M

      CMPX Discussion

      View Posts
      Tiger Money Tiger Money 2 days ago
      Gap filled 
      👍️0
      PonkenPlonken PonkenPlonken 2 days ago
      and they didnt even speak about it today!
      👍️0
      Tiger Money Tiger Money 2 days ago
      Some very good news out this morning!
      👍️0
      glenn1919 glenn1919 2 days ago
      CMPX..................................https://stockcharts.com/h-sc/ui?s=CMPX&p=W&b=5&g=0&id=p86431144783
      👍️0
      Tiger Money Tiger Money 5 days ago
      Thanks!
      👍️0
      glenn1919 glenn1919 6 days ago
      sideways................higher lows.....possible breakout
      👍️0
      Tiger Money Tiger Money 6 days ago
      What does your work tell you on this?  Thanks 
      👍️0
      glenn1919 glenn1919 7 days ago
      cmpx.........................https://stockcharts.com/h-sc/ui?s=cmpxp=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 3 weeks ago
      CMPX, under $2
      👍️0
      PonkenPlonken PonkenPlonken 1 month ago
      Sorry for the late reply, your question got lost in the mailbox.
      I believe 3-6$ isnt unreasonable if they publish a nice readout.

      i believe a handful of patients showed more than 30% tumor shrinkage in vegf monotherapy data... I havent seen similar to date...... Nobody listens to webcasts anymore - they probably need an anaylst note to alert them LOL
      VEGf space is full of scammers to... everyone jumped the train
      👍 1
      Tiger Money Tiger Money 2 months ago
      If so, where do you think that puts the stock?  Thanks 
      👍️0
      PonkenPlonken PonkenPlonken 2 months ago
      Wouldnt be surprised to see a partner announced in the 10q
      👍️0
      PonkenPlonken PonkenPlonken 2 months ago
      boom coming never before monotherapy data in VEGF space.... a place flooded by bio grifters
      👍️0
      Monksdream Monksdream 3 months ago
      CMPX under $2
      👍️0
      PonkenPlonken PonkenPlonken 3 months ago
      high volume yesterday
      👍️0
      PonkenPlonken PonkenPlonken 4 months ago
      EXCELLENT monotherapy data
      VEGF targeted agents usually need the chemo combination to even get a signifcant response. They get it in monotherapy.
      I think its going to run into the H1 2025 data.
      👍️0
      Monksdream Monksdream 4 months ago
      CMPX under $2
      👍️0
      glenn1919 glenn1919 4 months ago
      CMPX........................................https://stockcharts.com/h-sc/ui?s=CMPX&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 5 months ago
      CMPX....................https://stockcharts.com/h-sc/ui?s=CMPX&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 5 months ago
      CMPX under $2
      👍️0
      Monksdream Monksdream 10 months ago
      CMPX 10Q due 3/25
      👍️0
      Monksdream Monksdream 10 months ago
      CMPX 10Q due 3/18
      👍️0
      glenn1919 glenn1919 10 months ago
      CMPX....................................https://stockcharts.com/h-sc/ui?s=CMPX&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 10 months ago
      Cant say offhand
      Read the latest 10Q
      👍️0
      stockweiser stockweiser 10 months ago
      Do you know there current cash on hand?
      👍️0
      Monksdream Monksdream 10 months ago
      CMPX 10Q due March 11
      👍️0
      Monksdream Monksdream 12 months ago
      CMPX new 52=week low
      👍️0
      Monksdream Monksdream 1 year ago
      CMPX new 52 week low
      👍️0
      Monksdream Monksdream 1 year ago
      CMPX under $2
      👍️0
      Copilotdog Copilotdog 1 year ago
      Solid company
      👍️0
      Mktman2024 Mktman2024 2 years ago
      Compass to review latest phase 2 progress with CTX 009 and other items at ASCO Jan 19-21.
      Company moving slowly into the spotlight.
      👍️0
      Mktman2024 Mktman2024 2 years ago
      Reminder CMPX is Compass Therapeutics ,,,EF Hutton new target 10
      targets range from 8-15
      👍️0
      Mktman2024 Mktman2024 2 years ago
      https://www.streetinsider.com/Corporate+News/Compass+Therapeutics%2C+Inc+%28CMPX%29+doses+first+patient+in+Phase+1b+CTX-471+combo+with+KEYTRUDA/20920046.html

      now were talking!!
      👍️0
      Mktman2024 Mktman2024 2 years ago
      amazing no one posts on any CMPX boards except twitter ...and even then crickets
      👍️0
      Mktman2024 Mktman2024 2 years ago
      The proper company name associated with CMPX symbol
      Compass Therapeutics . If one were to review the 6 or 7 bispecifics currently approved for cancer, the efficacy of CTX 009 , CTX 471 and CTX 8371 in early trials is astounding...with a very unique Moa...still not understood by most analysts. It clearly warrants a collaboration with Merck on 471 and potentially many others. The stitchmab they have developed is a real game changing technology optimizing the best suitable mab combinations , along with Taxol, Keytruda and others ...supercharging the efficacy of current drug therapies. This stock has multiple undervalued assets.
      👍️0
      Mktman2024 Mktman2024 2 years ago
      Do you think they like their company ...a little??

      Compass Therapeutics, Inc. Insider Trading Activity (benzinga.com)
      👍️0
      NO birds Allowed NO birds Allowed 2 years ago
      dude WTF!!!! another ALLM
      👍️0
      NO birds Allowed NO birds Allowed 2 years ago
      is eh CEO still buying?
      👍️0
      Mktman2024 Mktman2024 2 years ago
      The relative outperformance continues stock sits at 3.05 .Phase 2/3 in US will begin Q4 ...more oustanding data to follow. 3X is easy with this one.
      👍️0
      Mktman2024 Mktman2024 2 years ago
      CEO continues to buy stock buys another 15000 filed 8/17 owns over 5.3 million shares

      https://ih.advfn.com/stock-market/NASDAQ/compass-therapeutics-CMPX/stock-news/88862025/statement-of-changes-in-beneficial-ownership-4
      👍️0
      Mktman2024 Mktman2024 2 years ago
      Now we're talking !! 3.00 then 3.27 news might be coming fairly soon
      New data plus CTX 009 US trial enrollment . winner..
      👍️0
      Mktman2024 Mktman2024 3 years ago
      Could the rocket be on the launching pad ?? volume building nicely for a name thats still under the radar.
      👍️0
      Mktman2024 Mktman2024 3 years ago
      Awaiting further data on CTX 009 and the expansion of trials to the US
      👍️0
      NO birds Allowed NO birds Allowed 3 years ago
      I forgot to ask, have you or brooklyn participated in this last raise?I am waiting for the next one at .05
      👍️0
      NO birds Allowed NO birds Allowed 3 years ago
      you must have guessed by now that we have a mutual friend involved in both of these stocks
      👍️0
      NO birds Allowed NO birds Allowed 3 years ago
      hello old friend, this looks so much better than the other
      👍️0
      Mktman2024 Mktman2024 3 years ago
      To present at Jefferies H/C conf. june 9th...will they join the recommended list there too?
      👍️0
      Mktman2024 Mktman2024 3 years ago
      CEO buys 60,000 more on 5/28 owns 5.2 +million
      👍️0
      Mktman2024 Mktman2024 3 years ago
      Still amazed no posts on any stock msg boards Its under the retail radar so far while its 67% institutionally owned 5 analysts cover targets 9 11 15 to name a few.....add to this recent institutional buying as well as insider buys...Founders came from Orbimed. I'm all in.
      👍️0
      Mktman2024 Mktman2024 3 years ago
      B of A health conf went great . more exposure to this company with some amazing drug discovery anti tumor tech. Waiting to see more coverage upgrades and target price increases .Major board members buying more at 2.50...company still well under the radar .My number one pick for 2022-2023. potential 5 to 10 X from here. Targets still way too low.
      👍️0

      Your Recent History

      NASDAQ
      CMPX
      Compass Therapeutics
      TSXV
      IC
      International Corona Cap...
      BIT
      NSCIT8809765
      IBRD
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads